39 related articles for article (PubMed ID: 23707200)
1. Specific cleavage of the lung surfactant protein A by human cathepsin S may impair its antibacterial properties.
Lecaille F; Naudin C; Sage J; Joulin-Giet A; Courty A; Andrault PM; Veldhuizen RA; Possmayer F; Lalmanach G
Int J Biochem Cell Biol; 2013 Aug; 45(8):1701-9. PubMed ID: 23707200
[TBL] [Abstract][Full Text] [Related]
2. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
Guyot N; Butler MW; McNally P; Weldon S; Greene CM; Levine RL; O'Neill SJ; Taggart CC; McElvaney NG
J Biol Chem; 2008 Nov; 283(47):32377-85. PubMed ID: 18799464
[TBL] [Abstract][Full Text] [Related]
3. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
Weldon S; McNally P; McElvaney NG; Elborn JS; McAuley DF; Wartelle J; Belaaouaj A; Levine RL; Taggart CC
J Immunol; 2009 Dec; 183(12):8148-56. PubMed ID: 20007580
[TBL] [Abstract][Full Text] [Related]
4. CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner.
Wilkinson RD; Magorrian SM; Williams R; Young A; Small DM; Scott CJ; Burden RE
Oncotarget; 2015 Oct; 6(30):29725-39. PubMed ID: 26358505
[TBL] [Abstract][Full Text] [Related]
5. Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions.
Hentschel J; Fischer N; Janhsen WK; Markert UR; Lehmann T; Sonnemann J; Böer K; Pfister W; Hipler UC; Mainz JG
J Cyst Fibros; 2015 May; 14(3):324-33. PubMed ID: 25286826
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult
Brown R; Small DM; Doherty DF; Holsinger L; Booth R; Williams R; Ingram RJ; Elborn JS; Mall MA; Taggart CC; Weldon S
Mediators Inflamm; 2021; 2021():6682657. PubMed ID: 33828414
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.
Brown R; Nath S; Lora A; Samaha G; Elgamal Z; Kaiser R; Taggart C; Weldon S; Geraghty P
Respir Res; 2020 May; 21(1):111. PubMed ID: 32398133
[TBL] [Abstract][Full Text] [Related]
8. Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity.
Laucirica DR; Garratt LW; Kicic A
Front Immunol; 2020; 11():595. PubMed ID: 32318073
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the Proteolytic Activity of Cysteine Cathepsins by Oxidants.
Lalmanach G; Saidi A; Bigot P; Chazeirat T; Lecaille F; Wartenberg M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178437
[TBL] [Abstract][Full Text] [Related]
10. Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.
McKelvey MC; Weldon S; McAuley DF; Mall MA; Taggart CC
Am J Respir Crit Care Med; 2020 Jan; 201(2):141-147. PubMed ID: 31626562
[No Abstract] [Full Text] [Related]
11. Cytokines IL-17, TNF and IFN-γ Alter the Expression of Antimicrobial Peptides and Proteins Disparately: A Targeted Proteomics Analysis using SOMAscan Technology.
Altieri A; Piyadasa H; Recksiedler B; Spicer V; Mookherjee N
Vaccines (Basel); 2018 Aug; 6(3):. PubMed ID: 30087279
[TBL] [Abstract][Full Text] [Related]
12. Site-specific and endothelial-mediated dysfunction of the alveolar-capillary barrier in response to lipopolysaccharides.
Janga H; Cassidy L; Wang F; Spengler D; Oestern-Fitschen S; Krause MF; Seekamp A; Tholey A; Fuchs S
J Cell Mol Med; 2018 Feb; 22(2):982-998. PubMed ID: 29210175
[TBL] [Abstract][Full Text] [Related]
13. Proteases Revisited: Roles and Therapeutic Implications in Fibrosis.
Kryczka J; Boncela J
Mediators Inflamm; 2017; 2017():2570154. PubMed ID: 28642633
[TBL] [Abstract][Full Text] [Related]
14. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.
Wilder CL; Walton C; Watson V; Stewart FAA; Johnson J; Peyton SR; Payne CK; Odero-Marah V; Platt MO
Int J Biochem Cell Biol; 2016 Oct; 79():199-208. PubMed ID: 27592448
[TBL] [Abstract][Full Text] [Related]
15. Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy.
Müller U; Hentschel J; Janhsen WK; Hünniger K; Hipler UC; Sonnemann J; Pfister W; Böer K; Lehmann T; Mainz JG
Mediators Inflamm; 2015; 2015():626530. PubMed ID: 26185365
[TBL] [Abstract][Full Text] [Related]
16. Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.
Keiser NW; Birket SE; Evans IA; Tyler SR; Crooke AK; Sun X; Zhou W; Nellis JR; Stroebele EK; Chu KK; Tearney GJ; Stevens MJ; Harris JK; Rowe SM; Engelhardt JF
Am J Respir Cell Mol Biol; 2015 Jun; 52(6):683-94. PubMed ID: 25317669
[TBL] [Abstract][Full Text] [Related]
17. Severe respiratory insufficiency during pandemic H1N1 infection: prognostic value and therapeutic potential of pulmonary surfactant protein A.
Tolosa MF; Palaniyar N
Crit Care; 2014 Aug; 18(4):479. PubMed ID: 25184962
[TBL] [Abstract][Full Text] [Related]
18. Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?
Ledford JG; Addison KJ; Foster MW; Que LG
Am J Respir Cell Mol Biol; 2014 Nov; 51(5):604-14. PubMed ID: 24960334
[TBL] [Abstract][Full Text] [Related]
19. miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production.
Weldon S; McNally P; McAuley DF; Oglesby IK; Wohlford-Lenane CL; Bartlett JA; Scott CJ; McElvaney NG; Greene CM; McCray PB; Taggart CC
Am J Respir Crit Care Med; 2014 Jul; 190(2):165-74. PubMed ID: 24940638
[TBL] [Abstract][Full Text] [Related]
20. Effects of airway surface liquid pH on host defense in cystic fibrosis.
Berkebile AR; McCray PB
Int J Biochem Cell Biol; 2014 Jul; 52():124-9. PubMed ID: 24560894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
